| Customization: | Available |
|---|---|
| Application: | Digestive System |
| Usage Mode: | For oral administration |
|
Still deciding? Get samples of US$ 100/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Lansoprazole Capsule 30mg
| Specification | 30mg 2x12/Blister/Box |
| Shelf life | 3Years |
| Storage | Store in a cool and dry place below 25ºC, protect from light |
Therapeutic indications
Healing and long-term management of reflux oesophagitis.
Healing and maintenance therapy for patients with duodenal ulcer.
Healing of benign gastric ulcer.
Lansoprazole is also effective in patients with benign peptic lesions that do not respond to H2- receptor antagonists.
The United States National Institute of Health have recommended that regimens to eradicate H. pylori in patients with peptic ulcer disease should contain both anti-secretory agents and antimicrobial agents (to which H. pylori has been demonstrated to be sensitive in vivo).
Dose and method of administration
Reflux oesophagitis
30 mg lansoprazole once daily for 4 weeks. The majority of patients will be healed after the first course. For patients who have not fully healed within this time, a further 4 weeks treatment using the same dosage regimen is indicated. For long-term management, a maintenance dose of 15 mg or 30 mg once daily can be used dependent upon patient response.
Duodenal ulcer
30 mg lansoprazole once daily for 4 weeks. For the prevention of relapse, the recommended maintenance dose is 15 mg once daily.
Eradication of H. pylori
Eradication of the infection is the single most important therapeutic intervention in patients with H. pylori positive peptic ulcer disease. The following combinations have been shown to be effective when used for 7 days: 30 mg twice daily plus two of the following antibiotics: amoxicillin 1g twice daily, metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily.
Long-term management
Capsules should only be used in certain situations including:
· In patients who have recurrent peptic ulceration where the pathogenesis of the ulcer is not related to H. pylori infection; or
· Where repeated eradication therapy is unsuccessful; or
· Patients who have a past history of perforation or bleeding from an ulcer.
Special populations
Renal impairment
There is no need to alter the dosage in patients with impaired renal function.
Since 2015, NINGBO VOICE BIOCHEMIC CO. LTD. is a professional company to offer one-package service for FPP (Finished Pharmaceutical Products ); APIs (Active Pharmaceutical Ingredients); Chemicals (Pharmaceutical Intermediates ); Veterinary Pharmaceuticals.that meet requirements of Standard GMP and current BP,USP version.
We will spare no efforts to meet your demands!
){kind=link}